Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?
Mahesh Swaminathan,
Farhad Ravandi
Affiliations
Mahesh Swaminathan
The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Texas
Farhad Ravandi
The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Texas